HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Angela Gritti Selected Research

Galactosylceramidase

1/2021Human iPSC-based neurodevelopmental models of globoid cell leukodystrophy uncover patient- and cell type-specific disease phenotypes.
1/2020In vitro Validation of Chimeric β-Galactosylceramidase Enzymes With Improved Enzymatic Activity and Increased Secretion.
11/2016Perspective on innovative therapies for globoid cell leukodystrophy.
1/2016Pervasive supply of therapeutic lysosomal enzymes in the CNS of normal and Krabbe-affected non-human primates by intracerebral lentiviral gene therapy.
6/2015Combined gene/cell therapies provide long-term and pervasive rescue of multiple pathological symptoms in a murine model of globoid cell leukodystrophy.
6/2014Therapeutic benefit of lentiviral-mediated neonatal intracerebral gene therapy in a mouse model of globoid cell leukodystrophy.
7/2013Region- and age-dependent alterations of glial-neuronal metabolic interactions correlate with CNS pathology in a mouse model of globoid cell leukodystrophy.
11/2012The galactocerebrosidase enzyme contributes to maintain a functional neurogenic niche during early post-natal CNS development.
10/2011Neural stem cell gene therapy ameliorates pathology and function in a mouse model of globoid cell leukodystrophy.
3/2009Specific determination of beta-galactocerebrosidase activity via competitive inhibition of beta-galactosidase.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Angela Gritti Research Topics

Disease

11Globoid Cell Leukodystrophy (Krabbe Disease)
01/2021 - 03/2009
8Lysosomal Storage Diseases (Lysosomal Storage Disease)
01/2021 - 06/2014
4Metachromatic Leukodystrophy (Sulfatide Lipidosis)
01/2017 - 06/2010
3GM2 Gangliosidoses (GM2 Gangliosidosis)
06/2022 - 06/2019
2Sandhoff Disease (Sandhoff's Disease)
06/2022 - 01/2020
2Disease Progression
07/2013 - 04/2009
2Demyelinating Diseases (Demyelinating Disease)
06/2010 - 04/2010
2Multiple Sclerosis
09/2009 - 04/2003
1Tay-Sachs Disease
06/2022
1Neurodegenerative Diseases (Neurodegenerative Disease)
01/2017
1Intellectual Disability (Idiocy)
12/2016
1Inflammation (Inflammations)
11/2012
1Sphingolipidoses (Sphingolipidosis)
10/2011
1Rare Diseases (Rare Disease)
06/2010
1Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
09/2009
1Neuroinflammatory Diseases
04/2009
1Infections
08/2008
1Neoplasms (Cancer)
10/2004

Drug/Important Bio-Agent (IBA)

10GalactosylceramidaseIBA
01/2021 - 03/2009
5EnzymesIBA
01/2020 - 06/2010
3Lysergic Acid Diethylamide (LSD)IBA
01/2020 - 04/2009
3Cerebroside-Sulfatase (Arylsulfatase A)IBA
01/2017 - 01/2014
2Proteins (Proteins, Gene)FDA Link
06/2019 - 06/2010
1G(M2) Ganglioside (Ganglioside GM2)IBA
06/2022
1Hexosaminidases (Hexosaminidase)IBA
01/2020
1MicroRNAs (MicroRNA)IBA
06/2019
1rho GTPase-activating proteinIBA
12/2016
1HydrolasesIBA
11/2016
1CeramidesIBA
01/2014
1SphingolipidsIBA
07/2013
1LipidsIBA
11/2012
1GlycosphingolipidsIBA
06/2010
1LigandsIBA
04/2009
1Cyclophilin AIBA
08/2008
1Proteasome Endopeptidase Complex (Proteasome)IBA
08/2008
1Proteasome InhibitorsIBA
08/2008

Therapy/Procedure

4Therapeutics
06/2022 - 04/2010
4Transplantation
01/2017 - 10/2004
3Investigational Therapies (Experimental Therapy)
06/2022 - 07/2013
1Cell- and Tissue-Based Therapy (Cell Therapy)
06/2022
1Hematopoietic Stem Cell Transplantation
04/2009
1Spinal Injections
04/2003